You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Analysts cited Guardant's strong liquid biopsy testing portfolio, specifically its Guardant360 assay, as reasons for their optimistic views.
The approach could allow doctors to more accurately and more easily identify which patients are free from cancer after radiation treatment.
The study supports the use of liquid biopsy tests to guide treatment decisions, especially in patients who can't be biopsied, or don't have enough tissue available for standard testing.
The company is developing a method that uses whole-genome sequencing to develop patient-specific assays for tracking tumor signals in the blood.
The company has developed a technology for isolating cancer DNA in urine along with specialized PCR assays to identify biomarkers that it believes will offer more accurate and sensitive detection of hepatocellular carcinoma.
The companies announced a strategic venture to provide comprehensive biomarker profiling to empower clinical trials in the immuno-oncology space.
The company's ctDx lung cancer assay identifies a variety of different actionable mutations in the blood of non-small cell lung cancer patients.
The partners aim to optimize DNA nanoball technology, accelerate the use of CTC technology, and work on a diagnostic tool for use at the point of care.
Researchers showed, retrospectively, that using a cutoff of 16 circulating DNA mutations they could identify patients who were more likely to respond to immunotherapy.
A Samsung University team found that mutation load measured with the Guardant360 liquid biopsy assay predicted response as well as tissue-based TMB.